RNAP III (n= 18) | Topo I (n= 24) | ACA (n= 15) | U3RNP (n= 9) | Th/To (n= 8) | |
---|---|---|---|---|---|
Prevalence of RP | 94% (16/17) | 96% (23/24) | 100% (15/15) | 100% (9/9) | 87% (7/8) |
Absence of RP at first visit (in RP positive cases) | 18% (3/16)1, 2 | 0% (0/23)2 | 0% (0/15) | 0% (0/9) | 0% (0/7) |
Scleroderma prior to RP | 31% (5/16)3, 4, 5 | 4% (1/23)3 | 0% (0/15)4 | 0% (0/9) | 0% (0/8) |
RP to scleroderma > 1 y | 25% (4/16) 6 | 53% (10/19) | 58% (7/12) | 50% (4/8) | 57% (4/7) |
RP to scleroderma (year, mean ± SD) | 1.5 ± 5.37, 8 (0.2 ± 1.2)9 | 4.1 ± 8.9 | 5.7 ± 5.87 | 1.1 ± 1.7 | 2.6 ± 3.4 |